Elevated levels of alpha-synuclein blunt cellular signal transduction downstream of Gq protein-coupled receptors

• Published in: Cellular signalling Vol. 30; pp. 82 - 91
• Main Authors: Volta, Mattia, Lavdas, Alexandros A, Obergasteiger, Julia, Überbacher, Christa, Picard, Anne, Pramstaller, Peter P, Hicks, Andrew A, Corti, Corrado
• Format: Journal Article
• Language: English
• Published: England 01.01.2017
• Subjects: alpha-Synuclein - metabolism; Animals; Calcium - metabolism; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases - metabolism; GTP-Binding Protein alpha Subunits, Gq-G11 - metabolism; Humans; Neuroblastoma - genetics; Neuroblastoma - metabolism; Phospholipase C beta - metabolism; Protein Binding; Receptors, G-Protein-Coupled - metabolism; Recombinant Proteins - metabolism; RNA, Messenger - genetics; RNA, Messenger - metabolism; Signal Transduction; ERK1/2; Gq protein-coupled receptors; Calcium; PLCβ1; Alpha-synuclein
• ISSN: 1873-3913
• DOI: 10.1016/j.cellsig.2016.11.012

Alpha-synuclein is central to Parkinson's disease pathogenesis and pathology, however its precise functions are still unclear. It has been shown to bind both PLCβ1 and MAPKs, but how this property influences the downstream signaling of Gq protein-coupled receptors has not been elucidated. Here we show that recombinant expression of alpha-synuclein in human neuroblastoma cells enhances cellular levels of PLCβ1 but blunts its signaling pathway, preventing the agonist-dependent rise of cytoplasmic Ca . In addition, overexpressing alpha-synuclein abolishes the activation of ERK1/2 upon agonist stimulation, indicating an upstream action in the signal transduction pathway. This data demonstrates that alpha-synuclein, when recombinantly expressed, interferes with the normal signaling of Gq-protein coupled receptors, which are then dysfunctional. Since many neurotransmitter systems utilize these receptor signaling pathways to mediate different abilities affected in Parkinson's disease, we argue this novel perspective might be helpful in designing treatment strategies for some of the non-motor symptoms in Parkinson's disease and synucleinopathies.